asthma news from FierceBiotech
NewsSPOTLIGHT: Anesiva inks $114M licensing deal
Transcription Factor Therapeutics has licensed the worldwide rights to Anesiva's NF-kB Decoy program, which includes the clinical drug candidate Avrina. NF-kB Transcription Factor Decoy inhibits Read more...
EmergingMed matches patients with clinical trials
Recruiting the right number of the right patients for any clinical trial can be a tough prospect. Now there are a host of new efforts to match a patient with a clinical trial, including a service Read more...
Critical Therapeutics, Cornerstone to merge
Critical Therapeutics is merging with Cornerstone Read more...
GSK, Amira sign $425M licensing pact
GlaxoSmithKline has agreed to pay Amira Pharmaceuticals up to $425 million for the exclusive worldwide rights to its FLAP inhibitors, including AM103 and other compounds within the current Read more...
Pfizer inks $25M research deal
Continuing the hot trend of biopharma companies partnering with research institutions, Pfizer has Read more...
Topigen adds $25M in new venture funds
Canada's Topigen Pharmaceuticals has gained $25 million in venture support for its clinical programs in respiratory disorders. The round brings the biotech's total financing to $71 million to date. Read more...
Press Release: AtheroGenics to Present at JPMorgan Healthcare ConferencePress Release: AtheroGenics to Present at JPMorgan Healthcare Conference Read more...SPOTLIGHT: Isis to sell $75M in stockIsis Pharmaceuticals has made a deal to sell $75 million in common stock to fund its clinical development programs. Azimuth Opportunity will buy the stock over 18 months at a slight discount. Much of that money will go to fund preclinical trials in diabetes, asthma and cardiovascular conditions. Report SkyePharma gets long-awaited Flutiform partnerThe UK's SkyePharma has inked a $165 million licensing deal ($25 million of which is up front) with Kos Pharmaceuticals for the U.S. marketing rights to Flutiform for asthma, its lead drug candidate. It's good news for SkyePharma, which has been seeking a partner on the drug for three years. The biotech company saw its shares surge on the news, even though some analyst's enthusiasm for the deal was tempered by the fact that SkyePharma hadn't landed a larger partner for the drug. Flutiform … Read more... | Press ReleasesNIH: National Asthma Guidelines Updated National Asthma Guidelines Updated New Approaches for Monitoring Asthma Control, Expanded Recommendations for Children The National Asthma Education and Prevention Program (NAEPP) today issued the Read more... |
Get more asthma coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets

